Fig. 2From: The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM studyProportion of patients with CM with ≥ 50% response (a) with MO and (b) without MO. A ≥ 50% response was defined as ≥ 50% reduction from baseline in the monthly average number of headache days of at least moderate severity over 12 weeks. CM, chronic migraine; MO, medication overuseBack to article page